| Keywords: |
cancer survival; treatment outcome; treatment response; review; fluorouracil; drug efficacy; capecitabine; temozolomide; positron emission tomography; radiopharmaceuticals; metabolism; diagnostic procedure; radiotherapy; diagnostic imaging; neuroendocrine tumor; population research; radiopharmaceutical agent; radiosensitivity; therapy effect; octreotide; receptor; radioisotope; drug therapy; stereotactic body radiation therapy; radioisotopes; everolimus; neuroendocrine tumors; electron; somatostatin receptor; theranostics; individualization; tumor ablation; single photon emission computed tomography; beta particles; gastroenteropancreatic neuroendocrine tumor; receptors, peptide; radiolabeling; humans; human; receptors, somatostatin; peptide receptor radionuclide therapy; edotreotide y 90; lutetium dotatate lu 177; <sup>177</sup>lu-dotatate; actinium dotatate ac 225; edotreotide lutetium lu 177
|
